Patents Examined by Blondel Hazel
  • Interferon administration vehicles
    Patent number: 4680175
    Abstract: An interferon preparation to be administered topically is provided comprising: (a) a therapeutically effective amount of one or more interferons; (b) a vehicle base compatible with the interferon or interferons being administered; (c) an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or interferons due to proteolytic agents; and (d) an effective amount of one or more anti-microbial agents. In certain preferred embodiments of the invention, the vehicle base is prepared from a mixture of polyethylene glycols or includes hydroxyethyl cellulose as a thickening agent.
    Type: Grant
    Filed: February 7, 1984
    Date of Patent: July 14, 1987
    Assignee: Interferon Sciences, Inc.
    Inventors: Leonard F. Estis, Sean A. Evans, Douglas Testa
  • Induction of immune response by immunization with encapsulated antigen-producing cells
    Patent number: 4680174
    Abstract: Cells such as genetically modified cells, e.g., hybridoma, which secrete an antigenic substance are encapsulated within capsule membranes having pores of dimensions sufficient to permit efflux of the antigens secreted by the cells but insufficient to permit traverse of the cells. The capsules are injected into an experimental animal where antigen passing through the pores of the capsule membrane induces lymphocytes to produce antibodies complementary to the antigen. The antibody may be harvested from the circulatory system of the animal. Preferably, lymphocytes are sampled from, e.g., the spleen of the animal, fused with a malignant cell line to produce a hybridoma which synthesizes the antibody in vivo, and the hybridoma is cultured to produce large quantities of monoclonal antibody.
    Type: Grant
    Filed: May 24, 1984
    Date of Patent: July 14, 1987
    Assignee: Damon Biotech, Inc.
    Inventors: Allan P. Jarvis, Jr., George A. Koch, Paul G. Abrams
  • Method for producing human leukocyte interferon alpha-2
    Patent number: 4680260
    Abstract: A method for producing human leukocyte interferon alpha-2 resides in that there is carried out submerged cultivation of a producer strain Pseudomonas species VG-84 carrying a plasmid pVG3 with an inserted gene of human leukocyte interferon alpha-2, said strain being deposited in the collection of microorganism cultures at the USSR Antibiotics Research Institute under Reg. No. 1742; said strain being cultivated in a nutrient medium, containing the sources of carbon and nitrogen, mineral salts and growth stimulants, under aeration in the presence of antibiotics, i.e., streptomycin or tetracycline, or a mixture of both, followed by isolation and purification of the end product.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: July 14, 1987
    Assignee: Vsesojuzny Nauchno-Issledovatelsky Institut Genetiki
    Inventors: Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov
  • Method and compositions for use in the treatment of fireblight
    Patent number: 4678750
    Abstract: A method and compositions for the treatment of fireblight disease in plants are described. The compositions include a phage for Erwinia amylovora which produces fireblight and an enzyme produced by the phage which depolymerizes a polysaccharide produced by Erwinia amylovora which is the cause of the fireblight disease. Purified enzyme preparations are described.
    Type: Grant
    Filed: October 18, 1984
    Date of Patent: July 7, 1987
    Assignee: Microlife Technics, Inc.
    Inventors: Peter A. Vandenbergh, Anne K. Vidaver
  • Method for promoting fusion of plant protoplast
    Patent number: 4677066
    Abstract: A method for promoting fusion of plant protoplasts comprising the steps of; (a) treating the plant protoplasts with a fusion agent, and then (b) incubating the resultant plant protoplasts in an incubation medium having an osmotic pressure lower than that required for maintaining the plant protoplasts in a stable form. This effectively promotes the fusion of the plant protoplasts at a higher fusion rate in a wider range of plants.
    Type: Grant
    Filed: December 23, 1983
    Date of Patent: June 30, 1987
    Assignee: Mitsui Petrochemical Industries, Ltd.
    Inventors: Shigeru Takahashi, Yasuhiro Maeda
  • Human cultured cell line
    Patent number: 4675291
    Abstract: This invention provides a novel cultured cell line which is derived from human T leukemic cells and which produces a colony-stimulating factor (CSF). This invention also provides a process for preparing such human cultured cell line, and a process of producing a CSF from such cell line.
    Type: Grant
    Filed: March 6, 1984
    Date of Patent: June 23, 1987
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yuichi Yamamura, Tadamitsu Kishimoto, Satoru Nakai, Yoshikatsu Hirai
  • Method for solubilization of interferon
    Patent number: 4675183
    Abstract: A method for increasing the solubility of interferon in water involves admixing an amino acid selected from the group consisting of arginine, histidine, lysine, hydroxylysine, ornithine, glutamine, .gamma.-aminobutyric acid, .epsilon.-aminocaproic acid and a salt thereof with interferon.
    Type: Grant
    Filed: April 25, 1985
    Date of Patent: June 23, 1987
    Assignee: Kwoya Hakko Kogyo Co., Ltd.
    Inventors: Yasuki Kato, Eiji Hayakawa, Kunitoshi Furuya, Akira Kondo
  • Pharmaceutical composition containing interferon in stable state
    Patent number: 4675184
    Abstract: A pharmaceutical composition for treating viral diseases, such as pasta, gargle, gel, ointment, suppository, spray, etc., containing interferon in a stable state which comprises an effective amount of human interferon, 15 to 60% by weight of a tri or higher polyhydric sugar alcohol and an organic acid buffer as stabilizers, and a conventional pharmaceutical carrier or diluent. The pH of the composition is about 3 to 6. Optionally, the composition can further contain as a stabilizer an anionic surfactant and/or albumin.
    Type: Grant
    Filed: January 4, 1984
    Date of Patent: June 23, 1987
    Assignees: 501 Sunstar Kabushiki Kaisha, 502 Toray Industries, Inc.
    Inventors: Kenji Hasegawa, Yasuo Sakano, Yasuhiro Katsuragi, Kenji Aimoto, Kunio Sugihara
  • Process and defined medium for growth of human epidermal keratinocyte cells
    Patent number: 4673649
    Abstract: Disclosed are novel methods and materials for generating in vitro cultured populations of human epidermal keratinocyte cells having a characteristic colony-forming efficiency of greater than 20%. Novel media preparations and procedures are disclosed that permit isolation, serum-free primary culture and serum-free serial subculture of human epidermal keratinocytes. Also disclosed are procedures and products employing keratinocyte cells grown in serum-free conditions for medical application, i.e., skin grafting.
    Type: Grant
    Filed: July 15, 1983
    Date of Patent: June 16, 1987
    Assignee: University Patents, Inc.
    Inventors: Steven T. Boyce, Richard G. Ham
  • Pharmaceutical composition containing a derivative of para-aminobenzoic acid as an active ingredient
    Patent number: 4673669
    Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 11, 1985
    Date of Patent: June 16, 1987
    Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
    Inventors: Chikao Yoshikumi, Yoshio Ohmura, Fumio Hirose, Masanori Ikuzawa, Kenichi Matsunaga, Takayoshi Fujii, Minoru Ohhara, Takao Ando
  • Immunogenic conjugates
    Patent number: 4673574
    Abstract: An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
    Type: Grant
    Filed: July 5, 1983
    Date of Patent: June 16, 1987
    Inventor: Porter W. Anderson
  • Crystalline human leukocyte interferon
    Patent number: 4672108
    Abstract: The crystallization of human leukocyte interferon is described. In a preferred embodiment crystalline recombinant human leukocyte interferon A (IFL-rA) is prepared.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: June 9, 1987
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hsiang-Fu Kung, David L. Miller, Sidney Pestka
  • Mixing process for cookies with storage-stable texture variability
    Patent number: 4668522
    Abstract: A process for controlling the size and texture of baked cookies through the use of specific mixing procedures is disclosed. In particular, adding the required total amount and type of sugar in varying portions at different points in the dough mixing sequence permits control of the size and texture of cookies having distributed therein discrete regions of crumb-continuous storage-stable distinct textures.
    Type: Grant
    Filed: August 30, 1984
    Date of Patent: May 26, 1987
    Assignee: The Procter & Gamble Company
    Inventors: James W. Cappel, Richard N. Cronemiller
  • Intravenous or intraperitoneal administration of a tripeptide compound for treating cancer
    Patent number: 4666887
    Abstract: A pharmaceutical composition for use in the treatment of malignant tumor cells in laboratory animals is disclosed. The pharmaceutical composition uses a pharmaceutically acceptable excipient with a tripeptide compound as the active ingredient. The tripeptide compound is formed from dichlorodiethylaminophenylalanine, parafluorophenylalanine, and methione.
    Type: Grant
    Filed: July 2, 1984
    Date of Patent: May 19, 1987
    Assignee: Proter S.p.A.
    Inventor: Augusto De Barbieri
  • Process for the large scale production of rabies vaccine
    Patent number: 4664912
    Abstract: In the large-scale production of rabies vaccine a cell stock comprising a VERO cell strain and a liquid nutritive medium containing serum and microcarriers suspended therein is successively passed into biogenerators of increasing volume. The last of the passages is carried out in a biogenerator having a volume of at least 150 liters. The liquid nutritive medium is drawn off at the end of the final passage and replaced with a serum-free liquid nutritive medium. The cell stock is inoculated in the last passage biogenerator with virus which is allowed to develop. The virus is then cultured, withdrawn and filtered. The filtered liquid suspension is then ultrafiltered, with inactivated beta-propiolactone and purified by zonal centrifugation or chromatography.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: May 12, 1987
    Inventors: Tadeusz J. Wiktor, Bernard J. Fanget, Pierre Fournier, Bernard J. Montagnon
  • Human T cell hybridomas which produce immunosuppressive factors
    Patent number: 4665032
    Abstract: A human T cell hybridoma comprising the product of:(A) fusion of:(i) a T cell from a patient with ARC or AIDS, wherein said T cell secretes an SSF capable of specifically inhibiting T cell-dependent responses while leaving other immune functions intact, and(ii) a human T cell line,followed by(B) selection from the product of (A) of a human T cell hybridoma which secretes an SSF capable of specifically inhibiting T cell-dependent responses while leaving other immune functions intact.
    Type: Grant
    Filed: June 28, 1984
    Date of Patent: May 12, 1987
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Jeffrey C. Laurence
  • Vaccines for gram-negative bacteria
    Patent number: 4663160
    Abstract: An immunizing composition is disclosed and comprises a detoxified polysaccharide from a gram-negative bacterium covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety. To prepare the above immunizing agent, the lipid A portion of lipopolysaccharide from a gram-negative bacterium is separated to give a detoxified polysaccharide. Reactive aldehyde groups are generated on the detoxified polysaccharide by selective oxidation. The detoxified polysaccharide is then covalently coupled to a detoxified protein from said gram-negative bacterium by means of a 4-12 carbon moiety having functionalities reactive to the aldehyde groups on the detoxified polysaccharide and to the carboxylic groups on the detoxified protein.
    Type: Grant
    Filed: March 14, 1983
    Date of Patent: May 5, 1987
    Assignee: Miles Laboratories, Inc.
    Inventors: Grace C. Tsay, Michael S. Collins
  • Babesiosis antigen and method for preparation
    Patent number: 4661348
    Abstract: A method of preparation of babesiosis antigen including the steps of: (i) forming a crude babesiosis antigenic fraction which is derived from a lysate of Babesia infected erythrocytes or soluble fraction thereof; (ii) forming monoclonal antibody to said babesiosis antigen fraction by cloning antibody producing cells from an animal having been administered thereto said babesiosis antigen fraction; (iii) absorbing said monoclonal antibody onto an absorbent and passing said babesiosis antigenic fraction through said absorbent whereby an antigen specific to said monoclonal antibody may be bound thereto; and (iv) separating the specific antigen from the monoclonal antibody.
    Type: Grant
    Filed: July 24, 1984
    Date of Patent: April 28, 1987
    Assignee: Commonwealth Scientific & Industrial Research Organization
    Inventor: Ian G. Wright
  • Preparation containing stabilized physiologically active substance
    Patent number: 4659570
    Abstract: A preparation of stabilized physiologically active substance which is produced by incorporating a physically and chemically modified gelatin in a physiologically active substance made of basic protein or polypeptide, such as interferons, specially gamma-interferon.
    Type: Grant
    Filed: April 25, 1985
    Date of Patent: April 21, 1987
    Assignee: Suntory Limited
    Inventor: Yoshitake Terano
  • Monoclonal antibody to human helper T cells
    Patent number: 4658020
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human helper T cells. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: April 14, 1987
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein